NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

Core Insights - NewAmsterdam Pharma Company N.V. has appointed Mark C. McKenna and Wouter Joustra as temporary non-executive directors to its Board of Directors, filling vacant positions until the next annual general meeting [1][2] - The company announced the departure of Sander Slootweg from its Board of Directors, effective July 16, 2024 [1] Company Overview - NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C) [6] - The company aims to address unmet needs for safe, well-tolerated, and convenient LDL-lowering therapies, particularly through its ongoing Phase 3 studies of obicetrapib, a CETP inhibitor [6] Leadership Experience - Mark C. McKenna brings over 20 years of pharmaceutical industry experience, having held leadership roles in various companies, including Prometheus Biosciences, which was acquired by Merck for approximately $10.8 billion in June 2023 [2][3] - Wouter Joustra has extensive experience in capital markets and life sciences investments, currently serving as a General Partner at Forbion, a global life sciences venture capital firm [3][4] Strategic Importance - The appointments of McKenna and Joustra are seen as strategic moves as NewAmsterdam approaches pivotal Phase 3 data readouts from multiple ongoing clinical trials [2] - Both new board members express confidence in the company's potential to impact the CVD treatment landscape significantly [3][5]